642 related articles for article (PubMed ID: 33800290)
1. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.
Jang DI; Lee AH; Shin HY; Song HR; Park JH; Kang TB; Lee SR; Yang SH
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800290
[TBL] [Abstract][Full Text] [Related]
2. Signalling pathways of the TNF superfamily: a double-edged sword.
Aggarwal BB
Nat Rev Immunol; 2003 Sep; 3(9):745-56. PubMed ID: 12949498
[TBL] [Abstract][Full Text] [Related]
3. [Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation].
Rodríguez Moreno C; López Vázquez P; Durán Parrondo C; Tato Herrero F; Lado Lado F
An Med Interna; 2006 Jan; 23(1):37-45. PubMed ID: 16542122
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.
Willrich MA; Murray DL; Snyder MR
Transl Res; 2015 Feb; 165(2):270-82. PubMed ID: 25305470
[TBL] [Abstract][Full Text] [Related]
5. TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases.
Bystrom J; Clanchy FI; Taher TE; Mangat P; Jawad AS; Williams RO; Mageed RA
Cytokine; 2018 Jan; 101():4-13. PubMed ID: 27639923
[TBL] [Abstract][Full Text] [Related]
6. Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders.
Tougaard P; Zervides KA; Skov S; Hansen AK; Pedersen AE
Immunopharmacol Immunotoxicol; 2016; 38(1):29-38. PubMed ID: 26810853
[TBL] [Abstract][Full Text] [Related]
7. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice.
Winsauer C; Kruglov AA; Chashchina AA; Drutskaya MS; Nedospasov SA
Cytokine Growth Factor Rev; 2014 Apr; 25(2):115-23. PubMed ID: 24405806
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms.
Ali MY; Akter Z; Mei Z; Zheng M; Tania M; Khan MA
Biomed Pharmacother; 2021 Feb; 134():111157. PubMed ID: 33370631
[TBL] [Abstract][Full Text] [Related]
9. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
10. The immunoproteasome: a novel drug target for autoimmune diseases.
Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death.
Suk K; Kim S; Kim YH; Kim KA; Chang I; Yagita H; Shong M; Lee MS
J Immunol; 2001 Apr; 166(7):4481-9. PubMed ID: 11254704
[TBL] [Abstract][Full Text] [Related]
12. Can we design a better anti-cytokine therapy?
Drutskaya MS; Efimov GA; Kruglov AA; Nedospasov SA
J Leukoc Biol; 2017 Sep; 102(3):783-790. PubMed ID: 28546502
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
Joyau C; Veyrac G; Dixneuf V; Jolliet P
Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
[TBL] [Abstract][Full Text] [Related]
14. TNF-mediated inflammatory disease.
Bradley JR
J Pathol; 2008 Jan; 214(2):149-60. PubMed ID: 18161752
[TBL] [Abstract][Full Text] [Related]
15. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.
Yang S; Wang J; Brand DD; Zheng SG
Front Immunol; 2018; 9():784. PubMed ID: 29725328
[TBL] [Abstract][Full Text] [Related]
16. Upside and Downside of Tumor Necrosis Factor Blockers for Treatment of Immune/Inflammatory Diseases.
Kunnumakkara AB; Thakur KK; Rana V; Bora B; Banik K; Khatoon E; Sailo BL; Shabnam B; Girisa S; Gupta SC; Aggarwal BB
Crit Rev Immunol; 2019; 39(6):439-479. PubMed ID: 32421957
[TBL] [Abstract][Full Text] [Related]
17. Role of the TWEAK/Fn14 pathway in autoimmune diseases.
Xu WD; Zhao Y; Liu Y
Immunol Res; 2016 Feb; 64(1):44-50. PubMed ID: 26659091
[TBL] [Abstract][Full Text] [Related]
18. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-α inhibitor-related autoimmune disorders.
De Stefano L; Pallavicini FB; Mauric E; Piccin V; Vismara EM; Montecucco C; Bugatti S
Autoimmun Rev; 2023 Jul; 22(7):103332. PubMed ID: 37062440
[TBL] [Abstract][Full Text] [Related]
20. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments.
Kollias G; Kontoyiannis D
Cytokine Growth Factor Rev; 2002; 13(4-5):315-21. PubMed ID: 12220546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
